Ortin Global Limited
NSE: ORTINGLOBE · Pharmaceuticals · sector
₹13.16NSE close 2026-10-26
Key numbers
Market cap₹11 cr
Price₹13.16
52w high / low₹21 / ₹11
P/E–Sector median 27.9x
P/B8.7xSector median 2.9x
Book value₹1.5
Dividend yield–Sector median 0.48%
ROE-56.2%Sector median 11.7%
ROCE-39.8%Sector median 12.3%
OPM-1,618.7%Sector median 14.0%
Debt / equity0.81xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-496.3x
Current ratio1.60x
Sales growth 3y-74.4%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹1 cr (FY26): borrowings are higher by ₹0 cr.
- Operating profit covered interest -496.3x in the last 12 months.
- Operating cash flow was below net profit in 1 of the last 5 years (FY23).
- Net loss in 8 of the last 8 quarters.
- Revenue was higher than a year earlier in 0 of the last 4 quarters.
- Debtor days went from 305 (FY24) to 728 (FY26).
- No dividend in the last 5 financial years.
- Price ₹13.16 on 2026-10-26: -38.2% from the 52-week high, +23.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹21.26 · low ₹10.58
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| OPM % | -900.0% | -366.7% | -400.0% | -500.0% | -5,000.0% | -500.0% | -933.3% | -3,400.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EPS (₹) | -0.58 | -0.13 | -0.20 | -0.22 | -0.62 | -0.07 | -0.01 | -0.42 |
| Revenue YoY | -80.0% | -66.7% | -40.0% | -75.0% | ||||
| Profit YoY | – | – | – | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 8 | 6 | 2 | 0 | 0 | 0 |
| EBITDA | 0 | 1 | -7 | -1 | -1 | -1 |
| Net profit | -0 | -0 | -8 | -1 | -1 | -1 |
| EPS (₹) | -0.49 | -0.08 | -9.89 | -1.04 | -0.91 | -1.12 |
| Revenue growth | -26.9% | -65.0% | -83.9% | -70.6% | -58.3% | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -74.4% | -58.5% | -58.3% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -14.7% (2y) | +11.1% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 11 | 3 | 2 | 1 |
| Borrowings | – | 6 | 2 | 0 | 1 |
| Cash & equivalents | – | 0 | 2 | 0 | 1 |
| Total assets | – | 21 | 7 | 4 | 5 |
| Fixed assets | – | 14 | 0 | 0 | 0 |
| Capital work in progress | – | 0 | – | – | 0 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 3 | 2 | 0 | 0 |
| Inventory | – | 3 | 0 | 0 | 0 |
| Payables | – | 2 | 0 | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 2 | -0 | -4 | -0 | -1 |
| Cash from investing | -0 | 0 | 12 | 0 | 0 |
| Cash from financing | -0 | 1 | -3 | 0 | 1 |
| Capex | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 2 | -0 | -4 | -0 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -0.6% | -284.7% | -42.8% | -59.8% |
| ROCE % | – | 1.8% | -142.5% | -37.5% | -32.2% |
| Debtor days | – | 207 | 305 | 279 | 728 |
| Inventory days | – | 280 | 5 | 34 | 0 |
| Payable days | – | 167 | 8 | 72 | 145 |
| Cash conversion cycle (days) | – | 320 | 302 | 241 | 583 |
| Working capital days | – | -27 | 744 | 2,302 | 5,202 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 1.24% |
| FIIs | 0.67% |
| Public (non-institutions) | 98.09% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.24% |
| Promoter group | % |
|---|---|
| Parveen Satija | 1.24% |
| Murali Krishna Murthy Sanka | 0.00% |
| Balaji Venkateswarlu Sanka | 0.00% |
| Sanka Sharath Kumar | 0.00% |
| Venkata Ratnamma Sanka | 0.00% |
| Venkata Sujatha Sanka | 0.00% |
| Venkata Subbamma Sanka | 0.00% |
| Lakshmi Sravani Dasari | 0.00% |
| Srinivasa Kumar Sanka | 0.00% |
| Sanka Hema Kumari | 0.00% |
| Sanka Tandav Krishna | 0.00% |
| Sanka Ravi Sankar | 0.00% |
| Sanka Satya Praveen Kumar | 0.00% |
| Sanka Naga Jyothi | 0.00% |
| Krishna Karthik Sanka | 0.00% |
| Public holders above 1% | % |
|---|---|
| Suresh Gadalay | 6.35% |
| Rajesh Poddar | 4.69% |
| MIR ATA ALI Khan | 2.62% |
| Nallavolu Jayamma | 2.23% |
| Prabha Rameshkumar Gupta | 1.12% |
| Saadvik Raghuram Yellareddygari | 1.05% |
| Aerva Jaipal Reddy | 1.02% |
11,151 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ORTINGLOBE | ₹11 cr | – | 8.7x | -56.2% | -39.8% | -1,618.7% | -74.4% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2023-09-22 | Other | Annual General Meeting |
| 2022-09-23 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ORTINGLOBE |
| BSE code | 539287 |
| ISIN | INE749B01020 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.